Blood transfusion for anaemia
Pro Research Analysisby 
Searched over 200M research papers
Blood Transfusion for Anaemia: A Comprehensive Overview
Introduction to Blood Transfusion for Anaemia
Blood transfusion is a common therapeutic intervention for anaemia, particularly in patients with advanced cancer, critical illnesses, and those undergoing major surgeries. This article synthesizes current research on the efficacy, risks, and management strategies of blood transfusion for anaemia.
Blood Transfusion in Advanced Cancer Patients
Anaemia is prevalent in 68% to 77% of patients with advanced cancer, yet only a minority receive blood transfusions. Studies indicate a subjective response rate of 31% to 70% post-transfusion, with improvements in fatigue and breathlessness noted early but waning by day 14. However, a significant proportion of patients (23% to 35%) die within two weeks of transfusion, highlighting the need for higher-quality studies to determine the effectiveness and appropriate patient selection for transfusion in advanced cancer .
Risks and Benefits of Blood Transfusion
While blood transfusions are essential for managing moderate-to-severe anaemia, they are associated with risks such as organ injury, increased morbidity, and mortality. Both anaemia and transfusion independently contribute to these adverse outcomes, necessitating a balance between the benefits and risks of transfusion . In patients with inflammatory bowel disease (IBD), adverse effects of allogeneic blood transfusion (ABT) include acute hemolytic reactions, bacterial contamination, and transfusion-related acute lung injury, among others. Evidence-based guidelines recommend restrictive transfusion protocols to minimize these risks .
Transfusion Strategies in Malignancies and Critical Care
In patients with malignant hematological disorders, conservative transfusion practices have shown equivalent outcomes to liberal practices, with reduced in-hospital mortality and fewer complications such as cardiac events and infections . Similarly, in critically ill patients, restrictive transfusion practices are associated with reduced morbidity and mortality, except in cases of acute coronary syndromes . The management of anaemia in critical care should aim to avoid oxygen supply dependency and maintain a moderate oxygen delivery reserve .
Blood Transfusion in Coronary Syndromes
The prevalence of anaemia in patients with acute coronary syndromes (ACS) ranges from 10% to 43%. A meta-analysis of randomized controlled trials found no significant differences in 30-day mortality or major adverse cardiovascular events between restrictive and liberal transfusion strategies. These findings support current guidelines recommending a restrictive transfusion strategy in anaemic patients with ACS .
Preoperative and Perioperative Blood Management
Preoperative anaemia is common in patients undergoing major elective surgery and is associated with poor outcomes. A randomized trial found that preoperative intravenous iron did not significantly reduce the need for blood transfusions compared to placebo . Perioperative blood management (PBM) emphasizes optimizing anaemia, managing bleeding, and avoiding unnecessary transfusions. PBM strategies include the use of tranexamic acid, meticulous haemostasis, and cell salvage techniques during surgery, as well as point-of-care coagulation tests to tailor transfusion prescriptions .
Conclusion
Blood transfusion remains a critical intervention for managing anaemia across various patient populations. However, the associated risks necessitate careful consideration of transfusion strategies. Restrictive transfusion practices and evidence-based guidelines are essential to optimize patient outcomes while minimizing adverse effects. Further research is needed to refine these strategies and improve the management of anaemia in different clinical settings.
Sources and full results
Most relevant research papers on this topic